If the sponsor discontinues clinical development of an investigational product, how long should sponsor-specific essential documents be retained?

• A. At least 2 years after formal discontinuation or regulatory requirements.
• B. Indefinitely.
• C. Only during development.
• D. No retention required.

Answer: (A)

The question is testing how long sponsor-specific essential documents must be kept after clinical development is halted.

Sponsors must preserve essential documents that demonstrate the trial was conducted in compliance with GCP and to support regulatory oversight. Even when development stops, regulators or inspectors may need to review these records later. The minimum retention period is at least 2 years after formal discontinuation of the product's development or after any applicable regulatory requirements. This provides a defined window to address any questions or actions that may arise from regulators, recalls, or post-discontinuation safety reviews. In practice, some situations may require keeping documents longer depending on regulatory obligations, but the stated minimum is 2 years after discontinuation or regulatory requirements. Retaining only during development or not retaining at all would leave the sponsor unprepared for future inquiries, and retaining indefinitely goes beyond the typical requirement unless specific regulations dictate it.